Harrow Health Inc
NASDAQ:HROW

Watchlist Manager
Harrow Health Inc Logo
Harrow Health Inc
NASDAQ:HROW
Watchlist
Price: 42.9 USD -2.23% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Harrow Health Inc?
Write Note

Harrow Health Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Harrow Health Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Harrow Health Inc
NASDAQ:HROW
Cash from Financing Activities
-$1.5m
CAGR 3-Years
N/A
CAGR 5-Years
-45%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash from Financing Activities
-$6.4B
CAGR 3-Years
27%
CAGR 5-Years
21%
CAGR 10-Years
5%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Financing Activities
$7.7B
CAGR 3-Years
N/A
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Cash from Financing Activities
-$5.7B
CAGR 3-Years
34%
CAGR 5-Years
14%
CAGR 10-Years
8%
Merck & Co Inc
NYSE:MRK
Cash from Financing Activities
-$6.3B
CAGR 3-Years
-72%
CAGR 5-Years
13%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Cash from Financing Activities
$5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Harrow Health Inc
Glance View

Market Cap
1.5B USD
Industry
Pharmaceuticals

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 182 full-time employees. The company went IPO on 2013-02-08. The firm owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. The firm holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The firm also owns royalty rights in four clinical stage drug candidates, which are being developed by Surface Ophthalmics and Melt Pharmaceuticals.

HROW Intrinsic Value
45.19 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Harrow Health Inc's Cash from Financing Activities?
Cash from Financing Activities
-1.5m USD

Based on the financial report for Sep 30, 2024, Harrow Health Inc's Cash from Financing Activities amounts to -1.5m USD.

What is Harrow Health Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-45%

Back to Top